Why Brookfield Residential put data governance ahead of AI
Similar Posts
The King can probably find £10m for EPC upgrades. Where will landlords find £9.87bn?
King Charles and Prince William could reportedly face a bill of around £10 million to improve the energy efficiency of rental properties across their estates. That is a hefty bill, even by royal standards, but the Government expects ordinary landlords across England and Wales to find nearly £9.9 billion. The Guardian has reported that King…
Student-Loan Borrowers Got Debt Relief, Credit Still Hit: New Lawsuit
Student-loan borrowers whose debt was wiped out are still being reported to credit bureaus, a new lawsuit says. On Thursday, the Project on Predatory Student Lending, a borrower advocacy group, filed a lawsuit against the Department of Education. It said that the department is violating the Fair Credit Reporting Act by reporting outstanding balances on…
ClearToken Passes Gate 2 in Bank of England DSS
ClearToken CSD Limited has been approved by the Bank of England to operate a Digital Securities Depository within the Digital Securities Sandbox, passing the milestone known as Gate 2. The approval allows the firm to issue and settle tokenised versions of existing securities under Bank supervision, within set limits, and makes it the second firm…
PNC is latest bank to say costs will rise alongside revenue
Key insight: Executives at both banks see major opportunities ahead, but expect to bear higher expenses in order to harness them. Supporting data: PNC raised its guidance for noninterest expense from up roughly 7% to up approximately 8.5%. Expert quote: “Some expenses, if you account for them as investments, they have very good returns, but…
Pharma ETF or Biotech ETF: Which Matches Your Investing Mindset?
The iShares U.S. Pharmaceuticals ETF (IHE +1.01%) offers a lower-cost entry into diversified pharmaceutical leaders, while the Invesco Biotechnology & Genome ETF (PBE +1.07%) targets high-growth biotech and genetic engineering firms. Both funds target the healthcare sector but with distinct strategic focuses. The healthcare sector often presents a choice between the high-growth potential of biotech…
Drug Pipeline Wins State Street Over on Healthcare
State Street Investment Management is turning positive on healthcare stocks after nearly a year of caution. The firm’s Q3 2026 sector outlook upgraded healthcare from neutral to positive. That marks the sector’s return to State Street’s list of favored trades. Key Takeaways: Healthcare earnings could jump to 19.3% growth by 2027. Institutional investors remain underweight…
